AI Article Synopsis
- Kes survival rates for relapsed/refractory osteosarcoma are low, but kinase inhibitors like lenvatinib have shown promise in treatment.
- A Phase II study revealed that the combination of lenvatinib with ifosfamide and etoposide exhibited anti-tumor activity in affected patients.
- The ongoing OLIE trial aims to compare the effectiveness of this combination treatment against ifosfamide and etoposide alone in young patients, with key goals focusing on progression-free survival and other safety and quality of life measures.
Article Abstract
While survival rates for patients with relapsed/refractory osteosarcoma are low, kinase inhibitors have shown efficacy in its treatment. The multikinase inhibitor lenvatinib, plus ifosfamide and etoposide, showed antitumor activity in a Phase II study in patients with relapsed/refractory osteosarcoma. This Phase II randomized controlled trial (OLIE) will assess whether the combination of lenvatinib + ifosfamide + etoposide is superior to ifosfamide + etoposide alone in children, adolescents and young adults with relapsed/refractory osteosarcoma. The primary end point is progression-free survival; secondary and exploratory end points include, but are not limited to, overall survival, objective response rate, safety and tolerability, pharmacokinetic characterization of lenvatinib in the combination treatment, quality of life and quantification of baseline unresectable lesions that are converted to resectable.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/fon-2021-0743 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!